Loading...
Loading...
GRTX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | -0.0M |
| Operating Expense | 11.1M |
| Operating I/L | -13.4M |
| Other Income/Expense | -2.3M |
| Interest Income | 0.4M |
| Pretax | -15.1M |
| Income Tax Expense | 2.1M |
| Net Income/Loss | -15.1M |
Galera Therapeutics, Inc. is a clinical stage biopharmaceutical company specializing in the development and commercialization of therapeutics for radiotherapy in cancer. Their lead product candidate, avasopasem manganese (GC4419), has completed Phase III clinical trial for severe oral mucositis in head and neck cancer patients, and is also being tested for esophagitis in lung cancer patients. Additionally, the company is developing GC4711, a product candidate for non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics generates revenue through the development and commercialization of these therapeutic products for radiotherapy-induced side effects in cancer patients.
